Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Trading 07-15 14:12:17 EDT

549.42

+12.56

+2.34%

High550.10	Low529.75	Vol126.29K
Open536.05	D1 Closing536.86	Amplitude3.79%
Mkt Cap12.67B	Tradable Cap7.69B	Total Shares23.06M
T/O68.56M	T/O Rate0.90%	Tradable Shares14.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":549.415,"timestamp":1784139137464,"preClose":536.86,"halted":0,"volume":126286,"delay":0,"changeRate":0.023385985173043158,"floatShares":13995100,"shares":23055522,"eps":-13.421304,"marketStatus":"Trading","change":12.555,"latestTime":"07-15 14:12:17 EDT","open":536.05,"high":550.095,"low":529.75,"amount":68562784.69049999,"amplitude":0.037896,"askPrice":549.94,"askSize":2,"bidPrice":548.77,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-13.421304,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784145600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":536.86,"preHourTrading":{"tag":"盘前","latestPrice":537.5055,"preClose":536.86,"latestTime":"07:00 EDT","volume":3,"amount":1619.27142,"timestamp":1784113214703,"change":0.6455,"changeRate":0.001202,"amplitude":0.012582},"postHourTrading":{"tag":"盘后","latestPrice":536.86,"preClose":536.86,"latestTime":"19:56 EDT","volume":3478,"amount":1867197.22,"timestamp":1784073395977,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.520777,"impliedVol":0.6121,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/MDGL/tweets","defaultTab":"tweets","newsList":[{"id":"2651140106","title":"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651140106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651140106?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:01","pubTimestamp":1784034072,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-biogen-biib-and-cadrenal-therapeutics-inc-cvkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-biogen-biib-and-cadrenal-therapeutics-inc-cvkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B894F039.SGD","PBE","CVKD","BMED","BK4588","BK4139","HCSG","BIIB","XLV","BK4137","BK4532","BK4007","LU0320765992.SGD","LU0029874061.USD","MDGL","LU0109394709.USD","LU0889565916.HKD","LABU","BK4585","IE00B19Z9P08.USD","LU0128526141.USD","IE00B19Z9Z06.USD","LU0234570918.USD","XBI","BK4581","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105476","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105476?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:40","pubTimestamp":1784032839,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-madrigal-pharmaceuticals-mdgl-and-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-madrigal-pharmaceuticals-mdgl-and-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","KRYS","HCSG","LABU","XBI","LU0320765992.SGD","BK4548","LU0128526141.USD","BK4137","LU0889565916.HKD","LU0029874061.USD","BK4139","BK4585","LU0109394709.USD","ALNY","PSCH","LU0882574055.USD","PBE","BK4581","BK4588","HELX","MDGL","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651984149","title":"Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2651984149","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651984149?lang=en_us&edition=fundamental","pubTime":"2026-07-14 02:56","pubTimestamp":1783968990,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals  announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.Truist kept its buy rating with a price target of $709.Price: 533.16","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194461","title":"Madrigal Wins Three New US Patents for MASH Drug Rezdiffra, Boosting IP Protection","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651194461?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:04","pubTimestamp":1783944253,"startTime":"0","endTime":"0","summary":"Madrigal wins three new US patents for MASH drug Rezdiffra, boosting IP protectionMadrigal Pharmaceuticals received three new U.S. patents covering Rezdiffra (resmetirom), strengthening protection in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL97T3ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","MDGL","BCDF","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679136","title":"Madrigal Grants New Hires 604 Stock Options, 2,952 Restricted Stock Units Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679136","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679136?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:06","pubTimestamp":1783368380,"startTime":"0","endTime":"0","summary":"Madrigal grants new hires 604 stock options, 2,952 restricted stock units under inducement planMadrigal Pharmaceuticals granted equity inducement awards on July 1, 2026 to seven new non-executive empl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL1bdRGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","MDGL","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BCDF","BK4112","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649767991","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649767991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649767991?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA6QLNM4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649067910","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649067910","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649067910?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368300,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., July  06, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322737/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDGL","BK4585","LCLG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648695066","title":"Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2648695066","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648695066?lang=en_us&edition=fundamental","pubTime":"2026-07-04 12:26","pubTimestamp":1783139182,"startTime":"0","endTime":"0","summary":"In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), triggering the start of IND-enabling studies for future clinical trials.\nThis progress adds an RNA-based approach to Madrigal’s largely Rezdiffra-focused pipeline, potentially broadening its toolkit for addressing a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDGL","BK4588","BK4585","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648522050","title":"Suzhou Ribo Hits First Milestone in Madrigal Sirna Collaboration for MASH Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2648522050","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648522050?lang=en_us&edition=fundamental","pubTime":"2026-07-02 08:01","pubTimestamp":1782950511,"startTime":"0","endTime":"0","summary":"Suzhou Ribo hits first milestone in Madrigal siRNA collaboration for MASH drug candidateSuzhou Ribo Life Science reached a first candidate drug nomination milestone in its siRNA partnership with Madri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL6QTG1Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK4588","BK4585","MDGL","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648563378","title":"Medicare Coverage Could Put These Obesity Drug Stocks In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2648563378","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648563378?lang=en_us&edition=fundamental","pubTime":"2026-06-30 23:17","pubTimestamp":1782832637,"startTime":"0","endTime":"0","summary":"The obesity and metabolic drug space is suddenly in the spotlight, and not just because of headlines around GLP-1 treatments. A Supreme Court ruling on executive power, Medicare’s move to start covering obesity drugs, and a record close for the Dow are all feeding into a new conversation about where risk and opportunity may sit in this corner of healthcare. This article looks at 3 stocks from our Healthcare Sector, Obesity and Metabolic Drug Manufacturers screener that appear particularly...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/medicare-coverage-could-put-these-obesity-drug-stocks-in-foc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDGL","BK4588","BK4585","RYTM","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077144","title":"Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077144?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158741,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 1,397 time-based restricted stock units to five new non-executive employees on June 15, 2026.Awards were issued under the company’s 2025 Inducement Plan.Restricted stock units vest in four equal installments on each of the first through fourth anniversaries of the grant date.Vesting is contingent on continued employment through each vesting date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL5rzlyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014013.SGD","LU2210149790.SGD","MDGL","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4585","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4112","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077971","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077971?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUABJKSX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645003282","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645003282","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645003282?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158700,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., June  22, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315603/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644460729","title":"Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2644460729","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644460729?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:07","pubTimestamp":1781726833,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals shareholders adopted a 2026 Stock Plan at the June 17 annual meeting.Shareholders also adopted a 2026 Employee Stock Purchase Plan at the same meeting.The board adopted a Nonqualified Deferred Compensation Plan, effective Aug. 1, for selected executives and non-employee directors.Eligible employees can defer up to 60% of base salary, up to 95% of the following year’s cash performance bonus.Deferred balances are payable on separation from service in a lump sum or installments of up to 10 years, or at an elected in-service date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Anal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL4KNWm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284369","title":"Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284369?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:20","pubTimestamp":1781180400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 08:20 ET (12:20 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281042","title":"BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281042?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:16","pubTimestamp":1781180201,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) has an average rating of Buy and mean price target of $678.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641284071","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades","url":"https://stock-news.laohu8.com/highlight/detail?id=2641284071","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641284071?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:26","pubTimestamp":1780691180,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) is back in focus after new Phase 3 and real world data presented at the EASL Congress 2026 linked its MASH drug Rezdiffra to improved liver and cardiovascular risk markers.\nSee our latest analysis for Madrigal Pharmaceuticals.\nDespite a recent pullback, including a 7 day share price return of down 4.5% and some profit taking after insider sales, Madrigal’s 1 year total shareholder return of about 80% and 5 year total shareholder return of over 3.5x suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new-1","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162385","title":"Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162385?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:06","pubTimestamp":1780603578,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 6,881 time-based restricted stock units to 20 new non-executive employees under its 2025 Inducement Plan.Restricted stock units vest in four equal annual installments over four years, subject to continued employment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3Pxs1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","LU2095319765.USD","BK4585","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","MDGL","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","NDAQ","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316289","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641316289?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:05","pubTimestamp":1780603500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA2QBPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162530","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162530?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:05","pubTimestamp":1780603500,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., June  04, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-ass","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3307086/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0156},{"period":"1month","weight":0.1167},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.0826},{"period":"1year","weight":0.6784},{"period":"ytd","weight":-0.0781}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.7,"avgChangeRate":0.037265},{"month":7,"riseRate":0.1,"avgChangeRate":-0.071062},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction